Dolat Capital: Suven Pharma Delivers Soft Q2, Growth Outlook Remains Intact
BQ Blue’s special research section collates quality and in-depth equity and economy research reports from across India’s top brokerages, asset managers and research agencies. These reports offer BloombergQuint’s subscribers an opportunity to expand their understanding of companies, sectors and the economy.
Dolat Capital Report
Suven Pharmaceuticals Ltd. reported soft Q2. Revenues declined 13% YoY (flattish QoQ) with Ebitda margins at 41% (down 500 basis points YoY and 600 basis points QoQ).
Lower revenues from specialty chemicals segment impacted margins. Further, lower profit share from Rising Pharma also impacted profits (down 20% YoY and QoQ).
Nonetheless, management reiterated its guidance of 15% growth in top-line and 15-20% growth in bottom-line with Ebitda margins at 40% plus for FY21.This implies a robust H2.
Click on the attachment to read the full report:
This report is authored by an external party. BloombergQuint does not vouch for the accuracy of its contents nor is responsible for them in any way. The contents of this section do not constitute investment advice. For that you must always consult an expert based on your individual needs. The views expressed in the report are that of the brokerage and do not represent the views of BloombergQuint.
Users have no license to copy, modify, or distribute the content without permission of the Original Owner.